ScholarLens Back to search
2007•Clinical cornerstoneRequires access

Reducing cardiometabolic risk through selective antagonism of CB1 receptors

Luc Van Gaal

Open publisher page 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rimonabant, Endocannabinoid system, Cannabinoid receptor, Medicine, Endocrinology, Internal medicine, Cannabinoid, Triglyceride

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Reducing cardiometabolic risk through selective antagonism of CB1 receptors — Research Paper | ScholarLens